KAYO-1732 / KayoThera - LARVOL DELTA

KAYO-1732, a 1st-in-class oral ALDH1a3 inhibitor, blocks retinoid nuclear receptor signalling to restore pancreatic beta cells and reverse type 2 diabetes (EASD 2026) - "KAYO-1732, a 1 st -in-class ALDH1a3 inhibitor, demonstrates β cell restoring capacity in preclinical models of T2D and cardiometabolic disease. These findings support a clinical approach designed to assess the restoration of functional β cell mass as a disease-modifying strategy for T2D."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • ALDH1A3